Application of dabigatran etexilate in preparation of medicine for treating leukemia

The invention relates to the technical field of medicines, in particular to application of dabigatran etexilate in preparation of a medicine for treating leukemia. The invention provides a medicine for treating MLL gene rearrangement acute myelogenous leukemia. The active ingredient of the medicine comprises dabigatran etexilate (DB). Researches find that the DB selectively reduces the activity of the MLL rearranged AML cells and induces the MLL rearranged AML cells to generate apoptosis in a concentration-dependent manner, and the DB affects the MLL rearranged AML cells on the gene level and the protein level. The invention provides a new potential therapeutic drug and a new therapy for leukemia, especially MLL gene rearrangement acute myelogenous leukemia, and provides a new idea for clinical application of dabigatran etexilate. 本发明涉及药物技术领域，尤其涉及达比加群酯在制备治疗白血病的药物中的应用。本发明提供了一种治疗MLL基因重排急性髓系白血病的药物，所述药物的活性成分包括达比加群酯(DB)。本发明经研究发现，DB以浓度依赖的方式选择性降低MLL重排AML细胞活力和诱导MLL重排AML细胞发生细胞凋亡，且DB在基因水平和蛋白水平上影响MLL重排AML细胞。本发明为白血病，尤其是M